Siemens Receives FDA 510(k) Clearance for IQ-SPECT Technology

December 12, 2008 – Siemens Healthcare announced that it has received FDA 510(k) clearance for IQ-SPECT technology.

Originally introduced at the 2008 Society of Nuclear Medicine Annual Meeting, June 14-18, in New Orleans, IQ-SPECT is Siemens newest Symbia feature that enables a comprehensive cardiac evaluation, including perfusion, attenuation correction and calcium scoring in just five minutes.

IQ-SPECT technology is achieved with SMARTZOOM collimators that magnify the heart while imaging the rest of the torso under traditional conditions. Combining this cardio-centric orbit acquisition technique with fast, 3D iterative reconstruction enables more confident diagnoses and improved patient comfort, enhancing image quality, speed, productivity and throughput.

IQ-SPECT is 510k-cleared and commercially available on all Symbia S and T systems, and is field upgradeable for any existing systems.

For more information: www.siemens.com/healthcare


Additional Content

News | SPECT Imaging

February 15, 2024 — According to a release issued by the U.S. Food and Drug Administration (FDA), Philips is recalling ...

Time February 15, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
News | Radiopharmaceuticals and Tracers

June 19, 2023 — NorthStar Medical Technologies, LLC, a global innovator in the development, production and ...

Time June 19, 2023
arrow
News | Nuclear Imaging

February 23, 2023 — Editor's note: This news item has been updated to reflect that the FDA has since updated its alert ...

Time February 15, 2023
arrow
News | SPECT-CT

September 12, 2022 — Royal Philips, a global leader in health technology, announced new milestones in the development of ...

Time September 12, 2022
arrow
Subscribe Now